Literature DB >> 20190791

Hematology: Trials and tribulations in primary CNS lymphoma.

Stephen M Ansell, S Vincent Rajkumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20190791     DOI： 10.1038/nrclinonc.2010.9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.

Authors:  D F Nelson; K L Martz; H Bonner; J S Nelson; J Newall; H D Kerman; J W Thomson; K J Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.

Authors:  Barbara Fisher; Wendy Seiferheld; Christopher Schultz; Lisa DeAngelis; Diane Nelson; S C Schold; W Curran; M Mehta
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

3.  A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.

Authors:  G M Mead; N M Bleehen; A Gregor; J Bullimore; D Shirley; R P Rampling; J Trevor; M G Glaser; P Lantos; J W Ironside; T H Moss; M Brada; J B Whaley; S P Stenning
Journal:  Cancer       Date:  2000-09-15       Impact factor: 6.860

4.  Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

Authors:  Igor T Gavrilovic; Adília Hormigo; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Long-term survival in primary CNS lymphoma.

Authors:  L E Abrey; L M DeAngelis; J Yahalom
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

6.  The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

Authors:  Janet E Olson; Carol A Janney; Ravi D Rao; James R Cerhan; Paul J Kurtin; David Schiff; Richard S Kaplan; Brian Patrick O'Neill
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

7.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors:  Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

8.  Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Authors:  Gaurav D Shah; Joachim Yahalom; Denise D Correa; Rose K Lai; Jeffrey J Raizer; David Schiff; Renato LaRocca; Barbara Grant; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

Authors:  Tracy Batchelor; Kathryn Carson; Alison O'Neill; Stuart A Grossman; Jane Alavi; Pamela New; Fred Hochberg; Regina Priet
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

10.  Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.

Authors:  Lauren E Abrey; Craig H Moskowitz; Warren P Mason; Michael Crump; Douglas Stewart; Peter Forsyth; Nina Paleologos; Denise D Correa; Nicole D Anderson; Dawn Caron; Andrew Zelenetz; Stephen D Nimer; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544
  10 in total
  2 in total

1.  Flows and flaws in primary central nervous system lymphoma.

Authors:  Andrés J M Ferreri; Gerald Illerhaus; Emanuele Zucca; Franco Cavalli
Journal:  Nat Rev Clin Oncol       Date:  2010-08       Impact factor: 66.675

2.  Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.

Authors:  Andrés J M Ferreri; Giada Licata; Marco Foppoli; Gaetano Corazzelli; Emanuele Zucca; Caterina Stelitano; Francesco Zaja; Sergio Fava; Rossella Paolini; Alberto Franzin; Letterio S Politi; Maurilio Ponzoni; Michele Reni
Journal:  Oncologist       Date:  2011-02-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.